Alturos’ research is built on a pre-clinical drug discovery program previously acquired from Galapagos (now Lakefront® Biotherapeutics).

ALT0135 is a derisked and potentially first-in-class, orally bioavailable small molecule with demonstrated central nervous system (CNS) penetration. This program aligns with Alturos’ strategy to advance innovative neuroprotective approaches with a new mechanism of action supported by robust in vitro and in vivo efficacy data. By addressing upstream disease drivers and modulating downstream pathways associated with neuronal toxicity, the platform offers a differentiated approach to treating neurodegenerative disorders.

“We are driven by the mission to provide patients with convenient oral and effective therapies fighting against neurodegenerative diseases,” said Jan Van der Schueren, PhD, co-founder and CEO of Alturos Therapeutics. “I am excited to take this optimised small molecule, ALT0135, which has demonstrated clear benefits in preclinical in vivo models, into the clinic.”

About Alturos Therapeutics

Alturos Therapeutics is a Dutch Belgian company, founded by a team of experienced industry veterans with proven track records in Alzheimer’s and other neurodegenerative diseases. The company is currently involved in a Series A funding round, aiming to accelerate development and advance its lead candidate into IND-enabling studies on the path to clinical proof-of-concept.